How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

Innovative mAbs

Organization name

Consutrade

Profile

We are an International Consulting Company devoted to the Pharma business, mainly in the field of Biotechnology. Consutrade partners are professionals with wide know-how and long experience in Biotech industry and business, up to 30 years in the area. Our daily work consists in finding companies of all over the world with something to offer. Usually we find small companies or development groups with limited resources which have developed promising products or technologies. We have a number of mAbs with serious potential to become new drugs in the field of Oncology. The companies we represent are open to several formulas of collaboration, from co-development to direct acquisition, including any intermediate stage. Our represented drugs are in advanced step of pre-clinical development and can prove relevant results for their intended targets.

We offer In-Licensing and/or Collaboration Projects for innovative mAbs in oncology field.Our mAbs are directed against:

  • -HER3
  • -Endosialin (CD248)
  • -LGALS3BP
  • -several bispecific antibodies

If you have question about this subject or want to know more about one or more of our molecules, please don’t hesitate to contact us.

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries